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Monte Carlo sim  u  la  tions and dose mea  sure  ments were per  formed for radionuclides in the
whole body and trunks of dif  fer  ent sizes in or  der to es  ti  mate ex  ter  nal ra  di  a  tion whole body
doses from pa  tients ad  min  is  tered with radiopharmaceuticals. Cal  cu  la  tions were per  formed
on  cy  lin  dri  cal  wa  ter  phan  toms  whose  height was 176 cm and for three body di  am  e  ters: of
24 cm, 30 cm, and 36 cm. The in  ves  ti  gated radionuclides were: 99mTc, 131I,  23I,  67Ga,  201Tl,
and  111In. Mea sured and MCNP-cal cu lated val ues were 2-6 times lower than the val ues cal cu -
lated by the point source method. Additionaly, the to  tal dose re  ceived by the pub  lic un  til a
radionuclide is com  pletely dis  in  te  grated was cal  cu  lated. The other pur  pose of this work is to
pro  vide data on whole body and fin  ger oc  cu  pa  tional doses re  ceived by tech  nol  o  gists work  ing
in nu  clear med  i  cine. Data showed a wide vari  a  tion in doses that de  pended on the in  di  vid  ual
tech nol o gist  and  the  po si tion  of  the  do sim e ter. 
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IN TRO DUC TION
Pa tients  ad min is tered  with  ra dio ac tive  ma te ri als
are  re tained  in  hos pi tals  af ter  di ag no sis  or  treat ment;  the
length of their re ten tion de pends on the level of ra di a tion
so as to en  sure that the whole body ra  di  a  tion doses that
are likely to be re  ceived by the pub  lic do not ex  ceed the
es tab lished  lim its.  While  pa tients  ad min is tered  very
short-lived  di ag nos tic  radiopharmaceuticals  like  99mTc
may  be  re leased  im me di ately,  those  with  ther a peu tic
sources of lon  ger ef  fec  tive half-lives and a high spe  cific
gamma ray con  stant like 131I are re  tained for a few days.
Pa tients with sources of in ter me di ate half-lives and in ter -
me di ate spe cific gamma ray con stant, such as 67Ga, 111In, 
and 201Tl, may or may not be re  tained and the de  ci  sion is
made on a case-by-case ba  sis [1].
A  re cent  ICRP  pub li ca tion  [1]  rec om mends  that
young  chil dren,  vis i tors  and  in di vid u als  not  en gaged
in  the  di  rect  care of pa  tients should be treated as
mem  bers of the pub  lic where a whole body dose limit
of 1 mS per year is ap  plied. Ac  cord  ingly, a good es  ti  -
mate of the dose from the pa  tient must be made for
dose as  sess  ment. Overestimations of the ra  di  a  tion
dose can lead to an un nec es sar ily pro longed stay in the
hos  pi  tal, while the ex  tra cost can put a bur  den and
cause dis  com  fort to the pa  tient. More  over, over  es  ti  -
ma  tion can be as  so  ci  ated with an ex  tra dose to the
med i cal staff. The rec om men da tion is that the de ci sion 
to hos pi tal ize or re lease a pa tient should be made on an
in di vid ual  case  ba sis  [1,  2].
The cal  cu  la  tion method sug  gested in US Reg  u  -
la  tory Guide 8.39 [3] on the re  lease of ra  di  a  tion pa  -
tients  ad min is tered  with  ra dio ac tive  ma te ri als,  based
on NRC Reg u la tion 10 CFR 35.75 [4], views all ac tiv -
ity in side the pa tient as a point source sub ject to the in -
verse square law; phys  i  cal half-life is con  sid  ered in  -
stead of the ef  fec  tive half-life. This method of dose
cal  cu  la  tion used by some re  search  ers [5, 6], has been
ques  tioned in a re  cent IAEA safety re  port [2] and by
many other in ves ti ga tors [6-9], as well. In point source 
cal cu la tions,  self-ab sorp tion  and  buildup  of  ra di a tion
within the pa  tient's body are ne  glected. Buildup and
self-ab sorp tion de pend mainly on the ra di a tion en ergy
and body size. The ref  er  ence val  ues for the body
height of Eu  ro  pean adults were taken as 176 cm for
males and 163 cm for fe  males [10, 11]; data for some
Asian pop  u  la  tions [12, 13] are also avail  able.
Lo cal cus toms should also be con sid ered when the
pro  tec  tion of the pub  lic is con  cerned. In breast  feed, an
in fant will re ceive a ma jor dose due to close con tact with
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In or  der to pro  vide ap  pro  pri  ate in  struc  tions and a better
de  sign of hos  pi  tal fa  cil  i  ties such as wait  ing rooms, the
dose re  ceived by the pub  lic was stud  ied by many re  -
search ers [5, 7, 14, 15]. Be cause 131I is more harm ful than 
other ra dio ac tive el e ments, it has been sub jected to more
in  ves  ti  ga  tion [7-9, 16, 17]. The guid  ance for work  ing
with pa tients ad min is tered with un sealed ra dio ac tive ma -
te  ri  als was given in ICRP 94 [1]. 
In this work, MCNP codes were used for whole
body dose cal  cu  la  tions to be com  pared with the mea  -
sured val  ues, so as to study the ef  fect of the body size
on the dose from the pa  tient and for com  par  i  son with
point source cal  cu  la  tions. This ap  proach can lead to a
better un  der  stand  ing and as  sess  ment of the dose to
work ers and the pub lic. It can also pro vide ap pro pri ate
in struc tions for care givers and med i cal staff and re sult
in a more eco  nom  i  cal prac  tice.
Data re cently re leased by the In ter na tional Com -
mis sion  of  Ra dio log i cal  Pro tec tion  on  the  ra di a tion
pro  tec  tion of nu  clear med  i  cal staff was pro  vided by
Vano  [18].  The  oc cu pa tional  dose  sig nif i cantly  in -
creases when the tech  nol  o  gist works in close prox  im  -
ity to the pa  tient dur  ing the in  jec  tion or trans  fer
to-and-from a trol ley [19]. An other re cent study on the 
ra  di  a  tion dose to the med  i  cal staff pro  vided by
Studbrock  et al., [20], con  cluded that the up  per limit
dose may be reached due to close con tact with 131I pa  -
tients. The dose to the hands has been as  sessed by
many in ves ti ga tors [21-24], and many stud ies have re -
ported  high  doses.  Fur ther more,  con tam i na tion  in  nu -
clear med  i  cine, even if it is mi  nor, can lead to a ma  jor
dose at an ex  trem  ity [25]. 
There is rel  a  tively few data on oc  cu  pa  tional
doses from de  vel  op  ing coun  tries [26-29], mean  ing
that more data is needed, es  pe  cially from the Mid  dle
East. Data pre  sented here re  fer to the doses re  ceived
by  ra di a tion  work ers  in  nu clear  med i cine.
METH ODS
MCNP  cal cu la tions  of  ex ter nal
doses us  ing phan  toms
To eval  u  ate the ex  ter  nal whole body dose from
the pa tient, cal cu la tions were per formed on cy lin dri cal 
wa  ter phan  toms with a height of 176 cm [10] and for
three body di  am  e  ters:  24 cm, 30 cm, and 36 cm. The
mul  ti  pur  pose MCNP-5 code [30] was used for 99mTc,
131I, 23I, 67Ga, 201Tl, and 111In sources. All of the cited
sources are di  ag  nos  tic im  ag  ing sources, with the ex  -
cep tion  of  131I which is both a ther  a  peu  tic and a di  ag  -
nos tic source. Be cause in many di ag nos tic pro ce dures
radiopharmaceutical el e ments ac cu mu late in trunk or -
gans, cal cu la tions were also per formed at the height of
65 cm (37% of the to  tal height, ac  cord  ing to ICRP 89
[10]), for di am e ters iden ti cal to those cited above. The
ra dio ac tive source was as sumed to be ho mo ge neously
dis  trib  uted in  side the phan  toms in the first model and
as a point source at the cen ter of the cyl in der in the sec -
ond model. Dose rates were cal  cu  lated at 0.05 cm and
100 cm away from the sur  face of the phan  tom and
along the line per  pen  dic  u  lar to the sym  me  try axis of
the phan tom from its mid dle. Com par i sons were made
with bare-point-source-cal  cu  lated val  ues [32] and
with mea  sured val  ues. The ANSI/ANS flux-to-dose
rate con  ver  sion fac  tors were con  sid  ered [31]. Gamma
ray  en er gies  and  their  cor re spond ing  in ten si ties  were
ob  tained from Unger and Trubey [32]. A to  tal of 107
his  to  ries were con  sid  ered, which leads to a max  i  mum
rel a tive  stan dard  de vi a tion  of  1.5%.
Mea sure ments  of  the  ex ter nal
dose from pa  tients
The mea  sured val  ues were ob  tained af  ter adult
male pa  tients were ad  min  is  tered with radiopharma-
ceuticals; the ex  ter  nal doses were mea  sured in con  tact
(1-5 cm from the sur face of the body) at sev eral lo ca tions
of the body and at 1 me ter away. The di rect ra di a tion dose 
rate was mea  sured us  ing GR 130M, sup  plied by
Exploronium, Can  ada.
Oc cu pa tional  dose  mea sure ments
The  in te grated  ex ter nal  doses  to  tech nol o gists
were mea  sured us  ing LiF TLD-100 do  sim  e  ters which
were used for both body mon  i  tor  ing and fin  ger dose
mea sure ments. A Harshaw-4000 sys tem chip reader was
used for the TLD eval u a tion. Three TLD cards were sup -
plied to each tech  nol  o  gist. One TLD card was worn on
the up per front (chest), one at the waist and one on the up -
per back (rear neck). The tech  nol  o  gists were also given
fin  ger TLD chips to mea  sure the fin  ger doses.
The mea  sure  ments were per  formed at King
Abdulaziz Uni  ver  sity Hos  pi  tal in Jeddah, Saudi Ara  -
bia, which has a ca  pac  ity of 500 beds. Ra  di  a  tion and
radionuclides were used for both di  ag  no  sis and ther  -
apy. The prep  a  ra  tion room was equipped with safety
equip  ment that in  cluded body shields, bench shields,
vial shields, sy  ringe shields and hold  ers, waste mod  -
ules and dis  pos  able con  tain  ers. The room was also
equipped with a cal  i  bra  tor and a fume hood with
proper  ven ti la tion.
RE SULTS  AND  DIS CUS SION
Cal cu lated  and  mea sured
doses from pa  tients
Fig  ure 1 shows the cal  cu  lated dose rates in
(mSv/h)/MBq at 1 m for the cy lin dri cal body phan tom,
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of the phanton, a bare point source and the mea  sured
val ues  for  99mTc.  No  sig nif i cant  dif fer ence  was  ob -
served when the source was a whole body or a trunk of
uni  form dis  tri  bu  tion or a point source at the cen  ter of
same di  am  e  ters. The dose de  creased when the di  am  e  -
ter (thick ness) in creased, be cause more ab sorp tion oc -
curred in the body. The mea  sured value was the av  er  -
age of the val  ues ob  tained for the bone, thy  roid, re  nal,
and car  diac ex  am  i  na  tions shown in fig. 2. The val  ues
of some mea  sured doses ob  tained from lit  er  a  ture are
also shown in fig. 1 [20, 33-35]. The work by
Mountford and O'Doherty [35] sum ma rized the re sults 
of the other au  thors; ac  cord  ingly, two dose val  ues in
the graph are from these au  thors. The value given by
Ejiri [33] was the av  er age of many val ues taken at dif -
fer ent  po si tions  of  the  do sim e ter,  with  vari a tions  of
±35%.
Ex cept for a sin gle mea sured value shown in fig.
1, dose cal  cu  la  tions of a bare point source are more
than 3 times the mea  sured val  ues and the MCNP-cal  -
cu  lated ones. Mea  sured and MCNP-cal  cu  lated val  ues
are close, in di cat ing that the mod els used for the cal cu -
la tions  were  ap pro pri ate.  The  dif fer ence  be tween  the
bare source and MCNP cal  cu  la  tions or mea  sured val  -
ues strongly de  pends on gamma ray en  ergy. With
lower en ergy, more ab sorp tion oc curs in the body. The
cor rect dose as sess ment of in di vid u als near the pa tient
should also con  sider radionuclide half-life. 99mTc is
widely used in nu clear med i cine, but be cause of its rel -
a tively short half-life of 6 hours, the haz ard as so ci ated
with it is more sig nif i cant to ra di a tion work ers than the 
pub lic.
The doses at 1 m for 67Ga and 201Tl are shown in
figs. 3 and 4. Gen  er  ally, sim  i  lar con  clu  sions were ob  -
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Fig ure 1. MCNP-cal cu lated, bare-source-cal cu lated, 
and mea  sured Tc-99m dose rates at 1 m
Fig  ure 2. Mea  sured Tc-99m dose rates at 1 m
Fig ure  3.  MCNP-cal cu lated,  bare-
source-cal cu lated, and mea sured Ga-67 dose rates at 1 m
Fig ure  4.  MCNP-cal cu lated,  bare-source-cal cu lated,
and mea  sured Tl-201 dose rate at 1 mtained: the dose de creased when the cyl in der thick ness 
in  creased, but was al  most in  de  pend  ent of the cyl  in  der
height. Ex cept for one mea sured value, the bare source 
pro  vides ap  prox  i  mately twice the dose as that of a cy  -
lin  dri  cal phan  tom of 30 cm and more than that of a
thicker phan  tom. The ef  fec  tive half-lives of 67Ga and
201Tl are ap prox i mately 3 days. Ac cord ingly, they stay
lon  ger in the body and give more doses.
For 111In, fig. 5 shows that the bare source dose
value was ap prox i mately 3.5 times the MCNP val ues and 
more than that for the mea sured val ues. The source emit -
ted 245 keV at 94%, 171 keV at 90% and 23 keV at 69%;
the last gamma en ergy of 23 keV eas ily ab sorbed into the
body gave a dose lower than those from a bare source.
The source ef  fec  tive half-life is 2.8 days, ne  ces  si  tat  ing
re al is tic  cal cu la tions  for  dose  as sess ments.
The dose val  ues for 131I are shown in fig. 6. The
source emits 365 keV gamma ray at 82%; the MCNP
value was ap  prox  i  mately half that of a bare source.
The source is widely used for ther  apy with a long ef  -
fec  tive half-life of ap  prox  i  mately 7.6 days. It is ex  -
tremely im  por  tant that a re  al  is  tic es  ti  mate of the dose
from pa  tients is made in or  der to avoid lon  ger than
nec es sary  hos pi tal iza tion  or  a  pre ma ture  re lease.
The dose rate of the 123I bare source is al  most 4
times the value cal  cu  lated us  ing MCNP (fig. 7) or the
value mea sured by Ejiri et al., [33]. The source emit ted 
159 keV at 89% and lower gamma rays of 27 keV and
31 keV at 70% and 16%, re  spec  tively. The lower
gamma rays were ab sorbed into the body be fore reach -
ing the out  side, which made the bare source value
much higher. Be  cause of this big dif  fer  ence in dose
val  ues and the ef  fec  tive half-life of ap  prox  i  mately 12
hours,  a  re al is tic  dose  es ti mate  is  nec es sary.  Fig ure  8
shows  the  com par i son  be tween  the  MCNP-cal cu lated
and bare source cal  cu  lated dose rates.
Con  tact dose rates are im  por  tant for as  sess  ing
the doses to in  fants [15], pa  tient spouses and other
mem  bers of the fam  ily [8, 9]. The mea  sured val  ues
showed  sig nif i cant  vari a tion,  de pend ing  on  the  mea -
sured po  si  tion on the body. Mea  sured con  tact dose
rates for 99mTc rel  a  tive to this work and other stud  ies
are shown in fig. 9. The val  ues ob  tained in this work
were ac quired at the high est con tact point for dif fer ent
di ag nos tic  ex am i na tions.  The  thy roid  had  the  high est
mea  sured value be  cause the neck has the small  est
body at  ten  u  a  tion. Dose val  ues given by Ejiri et al.,
[33] were the av  er  age of four val  ues at a point close to
the spine for 99mTc-ECD. Dose rates mea  sured by
Mountford and O'Doherty [35] were ob tained at 10 cm 
from the body.
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Fig ure  5.  MCNP-cal cu lated,  bare-source-cal cu lated,
and mea  sured In-111 dose rate at 1 m
Fig ure  6.  MCNP-cal cu lated,  bare-source-cal cu lated,
and mea  sured I-131 dose rate at 1 m
Fig ure 7. MCNP-cal cu lated, bare-source cal cu lated, and 
mea  sured I-123 dose rate at 1 mCal cu lated  pub lic  and
oc cu pa tional  doses
The pe  riod of time dur  ing which a pa  tient must
stay in the hos pi tal can be de cided based on dose com -
mit  ment, which is the to  tal dose re  ceived un  til the
radionuclide is com  pletely dis  in  te  grated, given by
D
D
= 0
lE
(1)
where D is the to tal dose, D0 – the ini tial dose rate, and 
lE –  the  ef fec tive  dis in te gra tion  con stant.  If  a  pa tient
re mains  hos pi tal ized  for  a  time  t and is dis  charged
from the hos pi tal af ter wards, the to tal dose re ceived by 
oth  ers is given as
D
D t E
E
=
- 0 exp( ) l
l
(2)
The to tal dose at 1 m and the to tal con tact dose in
eq. (1) are shown in tab. 1 by tak  ing a round fig  ure
dose rate from the graphs. This round value is close to
the mea  sured value or/and MCNP val  ues. The in  dic  a  -
tive ex am ple ac tiv ity is also pro vided in the ta ble. For a 
pa  tient ad  min  is  tered with 700 MBq of 99mTc, the to  tal
dose at 1 m is ap prox i  mately 90 mSv and the to  tal con -
tact dose is ap prox i mately 1.8 mSv. A pa tient ad min is -
tered with 200 MBq of 131I for im  ag  ing will have a to  -
tal dose of 2.1 mSv at 1 m and 79 mSv in to tal con tact;
con tact doses were es ti mated from data found in lit er a -
ture [20, 35]. High doses were ob  served for 131I and
111In. How  ever, a re  al  is  tic dose es  ti  mate can only be
ob tained  by  un der stand ing  the  spe cific  hab its,  so cial
life, trans  por  ta  tion and work of the pa  tient. A close
con  tact with a 131I or 111In pa  tient can eas  ily lead to a
dose that is above the con straint [1]. The rec om men da -
tion is that the dose re  ceived by young chil  dren, in  -
fants and in  di  vid  u  als not en  gaged in the di  rect care of
the pa  tient should not ex  ceed that of the pub  lic, i. e,
that of 1 mSv per year. A dose can eas  ily ex  ceed this
limit if proper pre  cau  tions are not taken [8, 9].
Oc cu pa tional  ra di a tion  dose
to  nu clear  tech nol o gists
Ta ble 2 shows whole body in te gral doses re ceived 
in 19 weeks by each of the 3 nu clear med i cine tech nol o -
gists; the doses were re corded us ing TLD chips at 3 po -
si  tions of the body. Ap  prox  i  mately 25-30 pa  tients were
treated per week. The dif  fer ences be tween the ob tained
val  ues can be at  trib  uted to many fac  tors that should in  -
clude the per  sonal hab  its and skills of the tech  nol  o  gist
ad min is ter ing  the  radiopharmaceuticals  and  car ing  for
the pa  tients, their body size (in par  tic  u  lar, height of the
tech nol o gist),  the  po si tion  of  the  do sim e ter  and  his/her
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Fig  ure 8. MCNP-cal  cu  lated and bare-source
cal  cu  lated dose rates at 1 m
Fig  ure 9. Tc-99m mea  sured con  tact dose rates
Ta  ble 1. Dose com  mit  ments at 1 m and con  tact dose com  mit  ment
Ef fec tive
half-life
[h]
Ini  tial dose rate at
1 m
[(mSvh
–1)MBq
–1]
Dose
com mit ment  at
1 m
[mSvMBq
–1]
Ini tial  con tact  dose
rate
[(mSvh
–1)MBq
–1]
Con tact  dose
com mit ment
[mSvMBq
–1]
In dic a tive
ac tiv ity
[MBq]
Dose
com mit ment
at 1 m [mSv]
Con tact  dose
com mit ment
[mSv]
99mTc 6 0.015 0.13 0.3 2.6 700 91 1  820
131I  (im ag ing) 182.4 0.04 10.5 1.5 395 200 2100 79  000
67Ga 70 0.015 1.5 0.45 300 46
201Tl 57.6 0.01 0.83 0.3 200 166
111In 67.2 0.04 3.9 1.5 200 776abil  ity to com  mu  ni  cate with the pa  tient. All tech  nol  o  -
gists in  cluded in this study were of in  ter  na  tional or  i  gin
and did not speak the lan guage of the pa  tients en trusted
to their care.
Ta ble 2 shows the doses ob tained from us ing fin -
ger TLD chips for over 8 weeks. The first tech  ni  cian
(no. 1) re  ceived much higher doses than the oth  ers.
The an  nual value if the same dose rate was to re  main
would amount to approx. 67 mSv. If the ac  tual dose to
the fin  ger  tip is 5 times the val  ues re  corded us  ing the
fin  ger do  sim  e  ter [23], the ac  tual an  nual dose would
amount to ap  prox  i  mately 335 mSv.
CON CLU SIONS
Fig  ure 1 and figs. 3-7 show that the mea  sured
val  ues of the whole body dose rates in this and other
rel e vant stud ies are close to MCNP-cal cu lated val ues.
Fig ure  8  shows  the  sig nif i cant  dif fer ence  be tween  the
MCNP-cal  cu  lated and bare source cal  cu  lated doses.
Point  source  cal cu la tions  [3]  highly  over es ti mate  the
dose. The data pre  sented here can be used for a better
es  ti  ma  tion of the dose to the pub  lic and ra  di  a  tion
work ers, par tic u larly since pa tient body size was taken 
into con  sid  er  ation. The dose val  ues at 1 m de  pended
mainly on body thick  ness in  stead of height; better
dose es  ti  ma  tion can be ob  tained based on the spe  cific
size  of  in di vid ual  pa tients.
The com  mit  ted dose per MBq at 1 m (tab. 1) for
131I and 111In was 10.5 and 3.9 mSv/MBq , re spec tively. 
These are high doses and spe  cial at  ten  tion needs to be
paid to pa  tients ad  min  is  tered with the said
radionuclides.  A  typ i cal  in dic a tive  com mit ted  to tal
dose re  ceived by a care  giver in pro  longed close con  -
tact to a pa  tient dur  ing a di  ag  nos  tic pro  ce  dure will be
ap prox i mately 2 mSv and 0.8 mSv for each of the men -
tioned radionuclides, re  spec  tively; the ac  tual dose re  -
ceived will de  pend largely on the time spent near the
pa  tient. Ac  cord  ingly, stay  ing in close prox  im  ity to the
pa  tient for a long time must be avoided. The other
radionuclides  ren dered  less  sig nif i cant  to tal  doses.
The body and fin ger oc cu pa tional doses for tech -
nol  o  gists pro  vided in tab. 2 showed a wide vari  a  tion
that de pends on the in di vid ual tech nol o gist and the po -
si  tion of the do  sim  e  ter. These doses can be sig  nif  i  -
cantly af fected by the prac tice, skill and hab its of in di -
vid  ual tech  nol  o  gists. Lower doses were re  corded by
the do  sim  e  ter placed in the up  per chest, while higher
doses were re corded by the do sim e ters placed near the
waist and the up  per back, which can be at  trib  uted to
the prac  tice fol  lowed. Re  ceiv  ing the high  est dose of
ap prox i mately 1 mSv in 19 weeks, the an nual dose can
amount to ap prox i mately 2.6 mSv which is well be low
the  oc cu pa tional  limit.
The high  est fin  ger dose re  corded was ap  prox  i  -
mately 11 mSv for 8 weeks; the an nual dose is ap prox i -
mately 67 mSv or 335 mSv af  ter a mul  ti  pli  ca  tion of 5
for the fin  ger tip dose [23]; al though it is be  low the ex  -
trem i ties dose limit of 500 mSv per year, it is still much 
too close to it. Proper mon  i  tor  ing of tech  nol  o  gists'
prac tices is needed; those with higher doses com pared
to oth  ers as  signed the same tasks should be closely
mon i tored.
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Abdul Rahim KINSARA,  Samir ABDUL-MADXID,  Vael EL-GAMAL,
Tarik ALBAGDADI,  Abdulraof MAIMANI,  Valid H. ABULFARAX
SPOQA[WE  IZLAGAWE  DOZAMA  OD  RADIOFARMAKA  APLICIRANIH 
PACIJENTIMA –  MEREWA  I  MONTE  KARLO  SIMULACIJA
Obavqene su Monte Karlo simulacije i merewa raspodele radionuklida u celom telu,
kao i u pojedina~nim delovima razli~itih dimenzija, kako bi se procenilo spoqa{we izlagawe
dozama od radiofarmaka apliciranih pacijentima. Za prora~une su kori{}eni cilindri~ni
vodeni fantomi visine 176 cm i tri razli~ita pre~nika: 24 cm, 30 cm i 36 cm. Ispitivani
radionuklidi su: 99mTc,  131I, 23I, 67Ga, 201Tl i 111In. Izmerene vrednosti i one dobijene MCNP
simulacijom bile su  dva do {est puta ni`e od vrednosti izra~unatih metodom ta~kastog izvora.
Odre|ena je ukupna spoqa{wa doza do trenutka u kojem je radionuklid potpuno dezintegrisan.
Drugi ciq ovog rada je da se prika`u podaci za efektivnu dozu i dozu za {ake tehni~ara koji rade na 
odeqewima nuklearne med i cine. Rezultati su pokazali {irok raspon doza, {to zavisi od ve{tine
tehni~ara i polo`aja no{ewa dozimetra.
Kqu~ne re~i: doza zra~ewa, radiofarmak, MCNP